Geneva, July 14 -- International Clinical Trials Registry received information related to the study (NCT04635423) titled 'Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)' on Nov. 5, 2020.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: Merck Sharp & Dohme LLC
Condition:
Warts, Genital
Neoplasms, Anal
Intervention:
Biological: V503
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: November 30, 2020
Target Sample Size: 1059
Countries of Recruitment:
Japan
To know more, visit https://clini...